الفهرس 
Review of literatureOnly 14 pages are availabe for public view
 |  | from | 161 |  |  |
| | | from | 161 | | |
Abstract
The Design And Development Of New Drug Delivery Systems Such As Glycerosomes And Self-Nanoemulsifying Drug Delivery Systems Can Enhance The Efficacy Of Some Existing Drugs. Also, These Delivery Systems Are Considered To Be Promising Systems Considering Drug Targeting, Localizing The Drug At The Site Of Action So Achieving Effective Local Therapeutic Concentration, Improving The Permeation Of Drugs And Reducing The Adverse Effects Due To Lower Dose Size.
The Goal Of This Thesis Is To Enhance The Solubility, Absorption, And The Local Efficacy Of Celecoxib And Cupferron Compounds On The Inflamed Tissues (Paw And Cheek Inflamed Tissues) And Avoid Systemic Toxicity Through The Formulation Of Two Different Nanocarrier Systems: Soft Innovative Glycerosomes Vesicles And Self-Nano Emulsifying Drug Delivery System (SNEDDS).
The Work In This Thesis Is Divided Into Three Chapters:
Chapter (1): Review Of Literature
Chapter (2): Formulation Design And Optimization Of Novel Soft Glycerosomes For Enhanced Topical Delivery Of Celecoxib And Cupferron.
Chapter (3): Formulation Development Of Self-Nanoemulsifying Drug Delivery System Of Celecoxib For The Management Of Oral Cavity Inflammation.
Chapter (2): Formulation Design And Optimization Of Novel Soft Glycerosomes For Enhanced Topical Delivery Of Celecoxib And Cupferron.
Celecoxib And Cupferron Loaded Glycerosomes Were Prepared By Hydrating Phospholipid-Cholesterol Films With Glycerol Aqueous Solutions (20–40%, V/V). The Design Of The Experiment Of Formulations Was Done Using Box-Behnken Design, Using Design-Expert® Software. The Optimized Formulations Were Examined Using High-Resolution Transmission Electron Microscope (TEM), Fourier-Transform Infrared Spectroscopy (FTIR) And Differential Scanning Calorimetry (DSC). The Optimized Formulations Were Formulated As A Gel Using Carbopol 934 P And The Anti-Inflammatory Effect Of These Gels Against A Reference Product, Indomethacin® Gel (1%), Was Evaluated Using Carrageenan-Induced Paw Edema Method Followed By Histopathological Studies.
from The Obtained Data In This Part, The Following Was Concluded:
• The Optimized Formulations (CLX2 And CUP1) Displayed A Mean Droplet Size Of 195.4 ± 3.67 And 301.2 ± 1.75 Nm, Entrapment Efficiency % Of 89.66 ± 1.73 And 93.56 ± 2.87 And Drug Release % Of 47.08 ± 3.37 And 37.60 ± 1.89 Respectively.
• In Vivo Study Of The Glycerosomal Gels Achieved Significant Remarkable Paw Edema Inhibition In Comparison With The Control And The Standard Groups (P < 0.05).
Chapter (3): Formulation Development Of Self-Nanoemulsifying Drug Delivery System Of Celecoxib For The Management Of Oral Cavity Inflammation.
SNEDDS Components Were selected Based On Their Ability To Dissolve The Drug And Pseudo- Diagram Was Plotted Depending On Solubility Results. These Results Revealed The Use Of Labrafil M 2515 CS As Oil, Tween 80 As A Surfactant And Polyethylene Glycol 400 As A Co-Surfactant. Eight SNEDDS Formulations Were Formulated And characterized For Particle Size, Viscosity, Drug Solubility, In Vitro Drug Release, And Ex Vivo Permeation Studies. The Anti-Inflammatory Effect Of The Optimum Formulations Against The Reference Product, Mundisal® Gel, Was Compared Using The Carrageenan-Induced Cheek Edema Method In Rats Followed By Histopathological Studies.
The Obtained Results Showed That:
• SNEDDS Formulations F3 And F5 Showed The Highest Capacity For Solubilizing Celecoxib Drug (1302.34 ± 30.67 And 1226.15 ± 28.65 Mg/Ml, Respectively).
• The Formulations F3 And F5 Have A Mean Droplet Size Of 116.9±1.78 And 124±1.87 Nm Respectively And A Complete In Vitro Drug Release (100%).
• F3 And F5 Achieved Significant Remarkable Cheek Edema Inhibition In Comparison With The Control Groups And The Standard group At (P < 0.05).